

Cat. No.: GC79548

Storage Store at -20°C

CC1(C)C(=O)N(CCCc2cc(Cl)ccc2Oc3cc(Br)cc(F)c3S(=O)(=O)Nc4ccoc4)N1

www.glpbio.com

Product Data Sheet

In Vivo, Nav1.7-IN-19 (150 mg/kg, p.o., daily for 3-7 days) significantly increases the mechanical withdrawal threshold (MWT) in SD rats with spinal nerve ligation pain model^[1]. Nav1.7-IN-19 (200 mg/kg, p.o., daily for 14 days) shows no obvious toxic reactions in rats^[1].

In Vitro, Nav1.7-IN-19 shows inhibition rates of 0.5%, 3.1%, and 24.6% at concentrations of 3, 10, and 30 μ M respectively^[1].

References:

[1]. Wu R, et al. Design, synthesis, structure-activity relationship (SAR) and analgesic effect studies of novel arylsulfonamides as selective Nav1.7 inhibitors. Eur J Med Chem. 2025 Dec 5;299:118069.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA